The Chimeric Therapeutics Ltd (ASX: CHM) share price is sliding in afternoon trade despite a positive update. Here’s what the company said.
The post Chimeric (ASX:CHM) share price edges lower despite positive update appeared first on The Motley Fool Australia. –
The Chimeric Therapeutics Ltd (ASX: CHM) share price is sliding in mid-afternoon trade. This comes despite the company announcing the successful completion of its CLTX CAR T phase 1 trial.
Established in 2020, Chimeric is developing a breakthrough cancer cell therapy drug for solid tumours. The company uses chlorotoxin, which comes from scorpion venom, to bind and direct T cells to target glioblastoma (GBM). Initial scientific research conducted at the City of Hope Cancer Centre in Los Angeles found promising anti-tumour activity from CAR T therapy.
At the time of writing, the biotechnology company’s shares are going for 29 cents apiece, down 1.6%.
What did Chimeric announce?
Investors appear unfazed by the company’s latest update, sending Chimeric shares lower.
According to its release, Chimeric advised it has passed the first checkpoint in the City of Hope’s phase 1 CLTX CAR T cell clinical trial. All patients in the first group that received the Chlorotoxin CAR T dose have exceeded the 28-day follow-up period without experiencing dose-limiting toxicities.
The dose-escalation study is seeking to assess Chlorotoxin CAR T’s safety and maximum tolerance in participants suffering from recurrent or progressive GBM.
While the first cohort received the minimum dosage limit, Chimeric will now move onto the second dosing level. Patients in this group will be administered via two methods – intratumoral (ICT) and intracranial intraventricular (ICV) at a total dose of 88 x 106 CAR T cells.
Chimeric hopes to recruit between 18 to 36 people with MMP2+ recurrent or progressive GBM across 4 different dose levels. Once the appropriate dosing amount is established, the company will then move to phase 2 trials.
Chimeric chief operating officer, Jennifer Chow commented on the achievement:
We are very pleased to have reached this significant milestone with our CLTX CAR T cell therapy as it enables us to advance the development of this important therapy for patients with progressive or recurrent Glioblastoma.
We look forward to further progressing the development of CLTX CAR T and to providing updates as we seek to bring the promise of cell therapy to life for more patients with cancer.
About the Chimeric share price
Since coming online to the ASX at the start of this year, the Chimeric share price has remained relatively flat. The company’s shares reached an all-time high of 44 cents in late January, before treading lower.
Based on the current share price, Chimeric has a market capitalisation of roughly $57 million.
Where to invest $1,000 right now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.
*Returns as of February 15th 2021
- NAB report finds the Australian economy on track to reach pre-COVID level
- Redbubble (ASX:RBL) share price crashes 20% on increased investments
- Could this help drive the Sydney Airport (ASX:SYD) share price long term?
- Why Megaport, Pointerra, Regis Resources, & Zip are charging higher
- Why the Spacetalk (ASX:SPA) share price is soaring 6% today
Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.